We trust our R&D competences to develop novel products and technologies
Research, development, and innovation
Innovation
Innovation is the foundation of Stratpharma’s success, which is why we rely on our R&D expertise to create novel products and technologies.
Commitment
Our ongoing R&D efforts aim to develop new formulations and indications that address unmet clinical needs.
Expertise
In line with our corporate strategy, Starpharma’s R&D focuses on our core areas of expertise — Aesthetic medicine and dermatology, plastic surgery, wound care, women’s health and oncology.
Progress in our key therapeutic areas
Stratpharma’s research programs will bring value to the therapeutic areas we serve.
Today, Stratpharma has more than 8 products under development focusing on innovative transdermal delivery systems and improved formulation stability.
Advanced wound care
We are developing new ways to tackle the global problem of chronic and recalcitrant wounds. New ways of improving wound nutrition and angiogenesis are the fundamental research areas where we investigate the field of diabetic ulcers, other venous insufficiency wounds and other hard-to-heal wounds.
Aesthetic medicine
We are seeking to find new solutions for indications that are challenging in Today’s available therapy options in aesthetic medicine, dermatology and plastic surgery. The focus in R&D lies with chronic inflammatory diseases of the skin, scars, stretch marks, post procedure care, hair transplantation and improved moisture vehicles.
Women’s health
In women’s health we are dedicated to deliver novel therapeutic options for undertreated and sometimes overlooked disorders such as vaginal atrophy, lichen planus, simplex or sclerosus caused by post-menopause or other mucosal conditions.
Oncology
Patients receiving radio-, chemo- or biological therapies to treat cancer will unfortunately experience certain levels of acute and sometimes chronic skin disorders. They can be a source of significant pain, discomfort and psychological distress. These side effects can result in treatment breaks. We are devoted to finding new solutions for patients facing a challenging therapy to increase their quality of life.
New-delivery vehicles
Stratpharma is developing new ways to improve drug administration resulting in improved patience compliance and overall clinical outcomes.
Science network
Further to sustaining our internal R&D proficiencies, Stratpharma maintains a global investigation network. Through research agreements with prominent specialists, state-of-the-art universities and promising start-ups, we continue to determine novel R&D models to provide ground-breaking products and therapy alternatives.
Collaborative innovation allows us to incorporate external knowledge and know-how into our R&D processes while accelerating development.
Stratpharma is taking advantage of advances in technology and its consequential development complexity; because of its globalization we are able to participate in transnational innovation partnerships and collaborations.
Collaborative innovation defines Stratpharma’s situation in this new environment.
We are committed to act as a magnet for breakthrough ideas. A significant proportion of our pipeline is obtained through partnerships with universities, biotechnological and formulation companies at a global scale.
Due to collaborative innovation we improve our R&D by creating value for patients, health care professionals and providers.